Date:11/5/2007

JPRD); Centocor R&D; and Ortho Biotech, including therapeutic area head for oncology and acting head of oncology research & development. Most recently he held the position of vice president, head of clinical oncology, responsible for strategic oversight and portfolio management of therapeutic oncology, hematology and supportive care clinical development programs for J&JPRD and Centocor's oncology development group. Before joining J&J, Dr. Zukiwski served in clinical oncology positions at pharmaceutical companies such as Hoffmann-LaRoche, Glaxo Wellcome and Rhone- Poulenc Rorer. Dr. Zukiwski holds degrees in pharmacy and medicine from the University of Alberta and the University of Calgary. He conducted his post- graduate training at St. Thomas Hospital Medical Center in Akron, Ohio, and the University of Texas M.D. Anderson Cancer Center. In his new role at MedImmune, Dr. Zukiwski will report to Ed Connor, M.D., executive vice president, clinical development and chief medical officer.

Also joining MedImmune is Dr. Timothy J. Hahn, who comes to his role as vice president, antibody manufacturing, building upon his more than 15 years experience in cell culture and live virus vaccine manufacturing with Merck & Co. In his position at MedImmune, he will be responsible for the antibody manufacturing strategy, including overall operations at MedImmune's cell culture manufacturing facility currently under construction in Frederick, Maryland, as well as existing sites in Frederick and Nijmegen, Netherlands. Dr. Hahn received both his doctorate and master of science degrees in chemical engineering from Stanford University and his bachelor of science degree from Lehigh University.

Timothy J. Maines brings to MedImmune more than 20 years of pharmaceutical, medical device and biologics industry experience as a microbiologist and quality professional. In his role as vice president, corporate quality assurance, he will be responsible for fortifying world-class quality s
'/>"/>

SOURCE MedImmune, Inc. Copyright©2007 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
2. MedImmune Celebrates Opening of New Pilot Lab at Gaithersburg Headquarters
3. MedImmune Recognized by Local Volunteer Organization for Its Employees Exceptional Commitment to Community Service within Montgomery County
4. MedImmune to Present RSV Surveillance and Cost-Effectiveness Data at American Academy of Pediatrics National Conference & Exhibition
5. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results